Could CAR T Therapy Become Adjustable After Infusion?

In an interview with Pharmacy Times, Christine Brown, PhD, and John Williams, PhD, of City of Hope discuss how an investigational meditope-enabled CAR T-cell platform could offer clinicians additional control after infusion. They explain the development steps needed before clinical use and where pharmacists could contribute to treatment delivery.

Unlike the fixed targeting of conventional CAR T cells, meditope-linked adapter molecules could be administered separately to modify selected cellular functions. Williams explains that the adapters’ pharmacological properties, including binding duration and clearance, would influence how long those effects persist. Withholding additional doses could potentially limit adapter-dependent activity, although the timing and reliability of that control require further investigation.

Brown describes adapter dosing as a potential safety mechanism that could allow different treatment windows depending on the intended function. The researchers also discuss future possibilities for imaging engineered cells or introducing a safety switch. These applications remain under development and should not be interpreted as established clinical capabilities.

At the time of the interview, the team was conducting investigational new drug–enabling studies for planned development in solid tumors and acute myeloid leukemia. Brown explains that initial clinical studies would evaluate the meditope-enabled CAR T-cell product itself, focusing on feasibility, safety, and maximum tolerated dose. Adapter-mediated redirection would be explored in later studies as those agents are developed.

For oncology pharmacists, this approach could introduce responsibilities beyond coordinating the cellular infusion. Brown emphasizes their involvement in delivering biologic adapters and determining appropriate doses based on patient monitoring. Williams highlights the importance of pharmacokinetic assessment and measuring treatment responses to help establish dosing regimens.

The discussion underscores the collaboration needed to translate this preclinical platform into patient care. Pharmacists would help connect adapter pharmacology with clinical observations as investigators determine whether adjustable cellular functions can be delivered safely and effectively in patients.